Find a Doctor
Timothy Robinson, MD, PhD
Specialty: Radiation Oncology
Program: Radiation Oncology
Locations: Moffitt Cancer Center
Dr. Timothy Robinson is an Assistant Member in the Department of Radiation Oncology at Moffitt Cancer Center. He is also a member of the Chemical Biology and Molecular Medicine Program. Dr. Robinson received his MD and PhD from Duke University School of Medicine. He recently completed his Radiation Oncology Residency at Duke. Dr. Robinson has a clinical interest in central nervous system (CNS) malignancies including both primary lesions and metastases. He also has an interest in hematologic malignancies, including leukemia, lymphoma, and multiple myeloma. Dr. Robinson’s primary research interest is in using large and complicated biological and clinical data to conduct clinical and translational research in ways that will ultimately benefit patients with cancer. Areas of interest include bioinformatics analysis of gene expression and alternative mRNA splicing, biomarker development, and novel combinations of radiation with targeted therapy. He holds patents and intellectual property related to novel therapeutics, biomarkers, and bioinformatics related to alternative mRNA splicing in cancer.
Education & Training
- Duke University of Medicine - Radiation Oncology
- Duke University of Medicine - MD/PhD
CLINICAL TRIAL 19575
Phase 3b Study for Management of Ocular Side Effects in Subjects with EGFR-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414)
Condition: Neurologic Oncology
Intervention: Depatuxizumab Mafodotin; Naphazoline; Prednisolone Acetate; Temodal (Temozolomide); Temozolomide
CLINICAL TRIAL 19582
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination with REGN2810 in Subjects with Newly-Diagnosed Glioblastoma (GBM)
Condition: Neurologic Oncology
Intervention: INO-5401; INO-9012; REGN2810 (Cemiplimab); Temodal (Temozolomide); Temozolomide
CLINICAL TRIAL 19648
Phase IB Study of Avelumab with Radiotherapy in Patients with Leptomeningeal Disease
Condition: Neurologic Oncology
Intervention: Avelumab; MSB00100718C (Avelumab)
CLINICAL TRIAL 19765
Phase Ib Study of Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases
Intervention: BMS-936558 (Nivolumab); Nivolumab
- Yuan Z, Grass GD, Robinson TJ, Kim S. Management of primary cutaneous CD4 small and medium pleomorphic T-cell lymphoma: A retrospective study. J Am Acad Dermatol. 2018 Oct;79(4):772-774. Pubmedid: 29857014.
- Ji KSY, Thomas SM, Roman SA, Czito B, Anderson KL, Frakes J, Adam MA, Sosa JA, Robinson TJ. Low- vs. High-Dose Neoadjuvant Radiation in Trimodality Treatment of Locally Advanced Esophageal Cancer. J Gastrointest Surg. 2018 Oct. Pubmedid: 30374818.
- Goffredo P, Robinson TJ, Frakes JM, Beck AC, Kalakoti P, Hassan I. The impact of location on the prognosis of squamous cell carcinomas of the anorectal region. J Surg Res. 2018 Nov;231:173-178. Pubmedid: 30278926.
- Goffredo P, Robinson TJ, Frakes JM, Utria AF, Scott AT, Hassan I. Comparison of Anal Versus Rectal Staging in the Prognostication of Rectal Squamous Cell Carcinoma: A Population-Based Analysis. Dis Colon Rectum. 2018 Nov. Pubmedid: 30398999.
- Grass GD, Mills MN, Ahmed KA, Liveringhouse CL, Montejo MJ, Robinson TJ, Chavez JC, Harrison LB, Kim S. Radiotherapy for early stage diffuse large B-cell lymphoma with or without double or triple hit genetic alterations. Leuk Lymphoma. 2018 Nov;1-8. Pubmedid: 30457458.
- B Figura N, Long W, Yu M, Robinson TJ, Mokhtari S, Etame AB, Tran ND, Diaz R, Soliman H, S Han H, Sahebjam S, Forsyth PA, Ahmed KA. Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience. Breast Cancer Res Treat. 2018 Jun;169(2):391-396. Pubmedid: 29392582.
- Goffredo P, Garancini M, Robinson TJ, Frakes J, Hoshi H, Hassan I. A National-Level Validation of the New American Joint Committee on Cancer 8th Edition Subclassification of Stage IIA and B Anal Squamous Cell Cancer. Ann Surg Oncol. 2018 Jun;25(6):1654-1660. Pubmedid: 29572706.
- Evans MK, Brown MC, Geradts J, Bao X, Robinson TJ, Jolly MK, Vermeulen P, Palmer GM, Gromeier M, Levine H, Morse MA, Van Laere S, Devi GR. XIAP Regulation by MNK Links MAPK and NFκB Signaling to Determine an Aggressive Breast Cancer Phenotype. Cancer Res. 2018 Apr;78(7):1726-1738. Pubmedid: 29351901.
- Ahmed KA, Berglund AE, Welsh EA, Naghavi AO, Kim Y, Yu M, Robinson TJ, Eschrich SA, Johnstone PA, Torres-Roca JF. The radiosensitivity of brain metastases based upon primary histology utilizing a multigene index of tumor radiosensitivity. Neurooncol. 2017 Aug;19(8):1145-1146. Pubmedid: 28379582. Pmcid: PMC5570253.
- Abuodeh Y, Ahmed K, Echevarria M, Naghavi A, Grass GD, Robinson TJ, Tomblyn M, Shah B, Chavez J, Bello C, El-Haddad G, Harrison L, Kim S. Priming radioimmunotherapy with external beam radiation in patients with relapsed low grade non-Hodgkin lymphoma. Ther Adv Hematol. 2017 Apr;8(4):129-138. Pubmedid: 28491264. Pmcid: PMC5405899.
- Harowicz MR, Robinson TJ, Dinan MA, Saha A, Marks JR, Marcom PK, Mazurowski MA. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset. Breast Cancer Res Treat. 2017 02;162(1):1-10. Pubmedid: 28064383. Pmcid: PMC5909985.
- Evans MK, Sauer SJ, Nath S, Robinson TJ, Morse MA, Devi GR. X-linked inhibitor of apoptosis protein mediates tumor cell resistance to antibody-dependent cellular cytotoxicity. Cell Death Dis. 2016 Jan;7:e2073. Pubmedid: 26821068. Pmcid: PMC4816185.
- Robinson TJ, Dinan MA, Li Y, Lee WR, Reed SD. Longitudinal Trends in Costs of Palliative Radiation for Metastatic Prostate Cancer. J Palliat Med. 2015 Nov;18(11):933-939. Pubmedid: 26241733. Pmcid: PMC4638209.
- Homa NJ, Salinas R, Forte E, Robinson TJ, Garcia-Blanco MA, Luftig MA. Epstein-Barr virus induces global changes in cellular mRNA isoform usage that are important for the maintenance of latency. J Virol. 2013 Nov;87(22):12291-12301. Pubmedid: 24027308. Pmcid: PMC3807935.
- Simmons LA, Dinan MA, Robinson TJ, Snyderman R. Personalized medicine is more than genomic medicine: confusion over terminology impedes progress towards personalized healthcare. Per Med. 2012 Jan;9(1):85-91. Pubmedid: 29783292.
- Robinson TJ, Forte E, Salinas RE, Puri S, Marengo M, Garcia-Blanco MA, Luftig MA. SplicerEX: a tool for the automated detection and classification of mRNA changes from conventional and splice-sensitive microarray expression data. RNA. 2012 Aug;18(8):1435-1445. Pubmedid: 22736799. Pmcid: PMC3404365.
- Dinan MA, Robinson TJ, Zagar TM, Scales CD, Curtis LH, Reed SD, Lee WR, Schulman KA. Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999-2007. Int J Radiat Oncol Biol Phys. 2012 Apr;82(5):e781-e786. Pubmedid: 22331001. Pmcid: PMC3418871.
- Miller HB, Robinson TJ, Gordân R, Hartemink AJ, Garcia-Blanco MA. Identification of Tat-SF1 cellular targets by exon array analysis reveals dual roles in transcription and splicing. RNA. 2011 Apr;17(4):665-674. Pubmedid: 21282347. Pmcid: PMC3062177.
- Robinson TJ, Dinan MA, Dewhirst M, Garcia-Blanco MA, Pearson JL. SplicerAV: a tool for mining microarray expression data for changes in RNA processing. BMC Bioinformatics. 2010 Feb;11:108. Pubmedid: 20184770. Pmcid: PMC2838864.
- Sessions OM, Barrows NJ, Souza-Neto JA, Robinson TJ, Hershey CL, Rodgers MA, Ramirez JL, Dimopoulos G, Yang PL, Pearson JL, Garcia-Blanco MA. Discovery of insect and human dengue virus host factors. Nature. 2009 Apr;458(7241):1047-1050. Pubmedid: 19396146. Pmcid: PMC3462662.
- Pearson JL, Robinson TJ, Muñoz MJ, Kornblihtt AR, Garcia-Blanco MA. Identification of the cellular targets of the transcription factor TCERG1 reveals a prevalent role in mRNA processing. J Biol Chem. 2008 Mar;283(12):7949-7961. Pubmedid: 18187414.